Perimenopausal period and mood disorders

The article is devoted to the possibilities of correction of neuropsychiatric disorders in perimenopause, a condition associated with the cessation of menstruation in a woman and a decrease in the level of ovarian steroid hormones (estrogen and progesterone) due to the loss of the ovarian follicular...

Full description

Bibliographic Details
Main Authors: N. V. Pizova, N. A. Pizov, A. V. Pizov
Format: Article
Language:Russian
Published: Remedium Group LLC 2021-04-01
Series:Медицинский совет
Subjects:
Online Access:https://www.med-sovet.pro/jour/article/view/6113
id doaj-3bcd5b432d2c49268fce91945f068289
record_format Article
spelling doaj-3bcd5b432d2c49268fce91945f0682892021-07-28T13:29:49ZrusRemedium Group LLCМедицинский совет2079-701X2658-57902021-04-010423023910.21518/2079-701X-2021-4-230-2395554Perimenopausal period and mood disordersN. V. Pizova0N. A. Pizov1A. V. Pizov2Yaroslavl State Medical UniversityYaroslavl State Medical UniversityYaroslavl State Pedagogical University named after K.D. UshinskyThe article is devoted to the possibilities of correction of neuropsychiatric disorders in perimenopause, a condition associated with the cessation of menstruation in a woman and a decrease in the level of ovarian steroid hormones (estrogen and progesterone) due to the loss of the ovarian follicular mass. It is known that biological and endocrine changes during this period are often accompanied by autonomic symptoms. In perimenopause, women may experience symptoms such as hot flashes and night sweats, insomnia, vaginal dryness, mood disorders, etc. Although most symptoms are not life-threatening, they can have a negative impact on the quality of life, physical and mental health of perimenopausal women. During menopause, women are at higher risk of developing depression, stress, anxiety and emotional disorders. In addition, during perimenopause, women experience not only depressive symptoms but also cognitive impairment, which may be related to changes in hormonal background. Drugs that are used in the treatment of mood disorders affect different neurotransmitters, in particular serotonin, norepinephrine and gamma-aminobutyric acid (GABA). One of the benzodiazepine derivatives is Tofisopam, first developed in Hungary and marketed in a number of European countries under the name Grandaxin. It is indicated for the treatment of neurotic and somatic disorders associated with tension, anxiety, autonomic disorders, lack of energy and motivation, apathy, fatigue, depressed mood and alcohol withdrawal syndrome, including during perimenopause. Tofisopam has good anxiolytic activity with no observable sedative, anticonvulsant, amnestic or muscle relaxant effects.https://www.med-sovet.pro/jour/article/view/6113perimenopauseneuropsychiatric disordersmood disordersdepressionstresshormonal backgroundtofisopam
collection DOAJ
language Russian
format Article
sources DOAJ
author N. V. Pizova
N. A. Pizov
A. V. Pizov
spellingShingle N. V. Pizova
N. A. Pizov
A. V. Pizov
Perimenopausal period and mood disorders
Медицинский совет
perimenopause
neuropsychiatric disorders
mood disorders
depression
stress
hormonal background
tofisopam
author_facet N. V. Pizova
N. A. Pizov
A. V. Pizov
author_sort N. V. Pizova
title Perimenopausal period and mood disorders
title_short Perimenopausal period and mood disorders
title_full Perimenopausal period and mood disorders
title_fullStr Perimenopausal period and mood disorders
title_full_unstemmed Perimenopausal period and mood disorders
title_sort perimenopausal period and mood disorders
publisher Remedium Group LLC
series Медицинский совет
issn 2079-701X
2658-5790
publishDate 2021-04-01
description The article is devoted to the possibilities of correction of neuropsychiatric disorders in perimenopause, a condition associated with the cessation of menstruation in a woman and a decrease in the level of ovarian steroid hormones (estrogen and progesterone) due to the loss of the ovarian follicular mass. It is known that biological and endocrine changes during this period are often accompanied by autonomic symptoms. In perimenopause, women may experience symptoms such as hot flashes and night sweats, insomnia, vaginal dryness, mood disorders, etc. Although most symptoms are not life-threatening, they can have a negative impact on the quality of life, physical and mental health of perimenopausal women. During menopause, women are at higher risk of developing depression, stress, anxiety and emotional disorders. In addition, during perimenopause, women experience not only depressive symptoms but also cognitive impairment, which may be related to changes in hormonal background. Drugs that are used in the treatment of mood disorders affect different neurotransmitters, in particular serotonin, norepinephrine and gamma-aminobutyric acid (GABA). One of the benzodiazepine derivatives is Tofisopam, first developed in Hungary and marketed in a number of European countries under the name Grandaxin. It is indicated for the treatment of neurotic and somatic disorders associated with tension, anxiety, autonomic disorders, lack of energy and motivation, apathy, fatigue, depressed mood and alcohol withdrawal syndrome, including during perimenopause. Tofisopam has good anxiolytic activity with no observable sedative, anticonvulsant, amnestic or muscle relaxant effects.
topic perimenopause
neuropsychiatric disorders
mood disorders
depression
stress
hormonal background
tofisopam
url https://www.med-sovet.pro/jour/article/view/6113
work_keys_str_mv AT nvpizova perimenopausalperiodandmooddisorders
AT napizov perimenopausalperiodandmooddisorders
AT avpizov perimenopausalperiodandmooddisorders
_version_ 1721273469524508672